Loading
Prostate Cancer Treatment and Research / Prostate Cancer Diagnosis and Treatment · Journal article
Scientific Reports · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This single-centre observational study identifies associations between baseline factors (PSADT ≥3 months, eGFR ≥70, treatment completion) and favourable outcomes in 93 mCRPC patients treated with radium-223. The findings are exploratory and subject to selection bias; the authors explicitly call for prospective validation before any change to clinical practice.
Single-centre observational cohort study. Patients with metastatic castration-resistant prostate cancer and bone metastases treated with radium-223; setting and other eligibility criteria not specified in the abstract.. Intervention: Radium-223 (5–6 cycles). n = 93. Not stated in the source text..
SSEs occurred in 26 of 93 patients (28.0%) Median rPFS 8.8 months (95% CI, 6.1–12.2); median OS 23.0 months (95% CI, 17.9–27.9) PSADT ≥3 months, eGFR ≥70 mL/min/1.73 m², and treatment completion (5–6 cycles) independently associated with lower SSE risk
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These prognostic associations may help identify mCRPC patients likely to benefit from radium-223, but should not yet guide treatment selection. The explicit acknowledgment of selection bias and call for prospective validation means clinicians should treat these findings as preliminary observations requiring confirmation.
Single-centre observational cohort study with exploratory multivariable analyses of prognostic factors in a small sample; the authors acknowledge potential selection bias and call for prospective validation, placing this in hypothesis-generating territory rather than confirmatory evidence.
As stated by the source record.
Quoted from the source exactly as published.
These prognostic associations may help identify mCRPC patients likely to benefit from radium-223, but should not yet guide treatment selection. The explicit acknowledgment of selection bias and call for prospective validation means clinicians should treat these findings as preliminary observations requiring confirmation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
We evaluated clinical factors associated with symptomatic skeletal events (SSEs), radiographic progression-free survival (rPFS), and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases treated with radium-223 (Ra-223). Of 101 enrolled patients, 93 were included in the final analysis (median follow-up, 25.2 months; interquartile range, 12.4–31.8). SSEs occurred in 26 patients (28.0%). Median rPFS and OS were 8.8 months (95% CI, 6.1–12.2) and 23.0 months (95% CI, 17.9–27.9), respectively. In multivariable analyses, prostate-specific antigen doubling time (PSADT) ≥ 3 months, estimated glomerular filtration rate ≥ 70 mL/min/1.73 m², and treatment completion (5–6 cycles) were independently associated with a lower risk of SSEs. Treatment completion, PSADT ≥ 3 months, and no prior androgen receptor signaling inhibitor use were independently associated with longer rPFS, whereas treatment completion was independently associated with improved OS. Treatment completion and favorable baseline tumor kinetics, particularly longer PSADT, were associated with better outcomes. Given the potential for selection bias and the exploratory nature of these observational findings, prospective studies are warranted to determine whether initiating Ra-223 during periods of lower disease activity improves outcomes and to clarify the optimal timing of treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.